NCT05325866 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05325866
Title	A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)
Acronym	FORTITUDE-301
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Amgen
Indications	intrahepatic cholangiocarcinoma head and neck squamous cell carcinoma cervix carcinoma colorectal adenocarcinoma Advanced Solid Tumor pancreatic ductal adenocarcinoma ovary epithelial cancer endometrial adenocarcinoma esophagus squamous cell carcinoma triple-receptor negative breast cancer
Therapies	Bemarituzumab
Age Groups:	senior \| adult
Covered Countries	USA \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG

Additional content available in CKB BOOST